Delcath Systems, Inc. DCTH
19.24 USD -0.46 (-2.34%)
Regular-session close
19.35 +0.11 +0.57%
After hours · Nov 19, 7:23 PM ET
18.99 Day range 19.89
8.12 52-week range 22.51
- YTD
- +90.50%
- 1 year
- +126.09%
News
businesswire.com Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of…
zacks.com Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our…
zacks.com Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy? Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 27.7%: Read This Before Placing a Bet The consensus price target hints at a 27.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
businesswire.com Delcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer Treatment QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the…benzinga.com HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $36 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $32 to $36.
benzinga.com Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results U.S. stocks surged Monday, led by a 2.1% S&P 500 gain; NRG jumped on strong results, while Zura Bio plunged 75% after trial failures.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com CNH Industrial, Planet Labs, Ferguson Enterprises And Other Big Stocks Moving Higher On Monday U.S. stocks rallied Monday; CNH surged 13.5% after strong Q3 results and raised guidance, while several stocks posted double-digit gains.
seekingalpha.com Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcript Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcriptbenzinga.com BTIG Maintains Buy on Delcath Systems, Raises Price Target to $25 BTIG analyst Marie Thibault maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $21 to $25.
marketbeat.com Delcath Systems Q3 Earnings Call Highlights Delcath Systems NASDAQ: DCTH reported record third-quarter revenue of $35.1 million, up 71% from a year earlier, as use of its HEPZATO KIT increased across U.S. treatment centers. The company also…
zacks.com Delcath Systems, Inc. (DCTH) Q3 Earnings and Revenues Top Estimates Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to earnings of $0.02 per share a year…
benzinga.com Delcath Systems Q3 2026 Earnings Call Transcript Delcath Systems (NASDAQ:DCTH) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com Delcath Systems Raises FY2026 Sales Guidance from $104.000M-$108.000M to $115.000M-$117.000M vs $106.507M Est Delcath Systems (NASDAQ:DCTH) raises FY2026 sales outlook from $104.000 million-$108.000 million to $115.000 million-$117.000 million vs $106.507 million estimate.
benzinga.com Delcath Systems Q3 EPS $0.17 Beats $(0.09) Estimate, Sales $35.102M Beat $26.027M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.09) by 312.5 percent. This is a 750 percent increase over earnings of…
businesswire.com Delcath Systems Reports Third Quarter 2026 Results and Business Highlights QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial…
seekingalpha.com Delcath Systems: Intriguingly Poised Ahead Of Q3 Earnings Delcath Systems, which has outperformed other Russell 2000 stocks and healthcare equipment makers by 3x and 8x this year, is due to publish Q3 results on the 9th of Nov. The probability of a topline…
businesswire.com Delcath Systems to Participate in Upcoming Investor Conferences QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced…
businesswire.com Delcath Systems to Host Third Quarter 2026 Earnings Call QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it…benzinga.com Delcath Systems Presents Data Regarding Its Clinical Development Programs At European Society For Medical Oncology Congress 2026; Presents Publication Of Analysis Of Percutaneous Hepatic Perfusion With Melphalan Using CHEMOSAT Hepatic Delivery Systems Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical…
businesswire.com Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced…
defenseworld.net Analysts Set Delcath Systems, Inc. (NASDAQ:DCTH) PT at $23.17 Shares of Delcath Systems, Inc. (NASDAQ: DCTH - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm,…
zacks.com Are Medical Stocks Lagging Delcath Systems (DCTH) This Year? Here is how Delcath Systems, Inc. (DCTH) and Encompass Health (EHC) have performed compared to their sector so far this year.
businesswire.com Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of…
zacks.com Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH VLO, PBF, FET and DCTH screen as low-beta picks as volatility rises, backed by refining, energy-equipment and liver-cancer growth drivers.
zacks.com 5 Stocks With Recent Price Strength Buoyed by a Strong August EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
businesswire.com Delcath Systems to Participate in Upcoming Investor Conferences QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced…
zacks.com What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now? Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
